|AHFS/Drugs.com||International Drug Names|
|Oral, IM, IV|
|Metabolism||The peak analgesic effect is seen within 30–60 minutes and lasts about 3–4 hours|
|Elimination half-life||Half-life (1.4–4 hours)|
|Excretion||The drug is rapidly metabolized to the glucuronide, and mostly excreted in the urine|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||233.355 g·mol−1|
|3D model (JSmol)|
|(what is this?) (verify)|
Meptazinol (trade name Meptid) is an opioid analgesic developed by Wyeth in the 1970s. Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics (childbirth).
Meptazinol is a 3-phenylazepane derivative, whereas the other phenazepanes like ethoheptazine and proheptazine are 4-phenylazepanes.
A partial μ-opioid receptor agonist, its mixed agonist/antagonist activity affords it a lower risk of dependence and abuse than full μ agonists like morphine. Meptazinol exhibits not only a short onset of action, but also a shorter duration of action relative to other opioids such as morphine, pentazocine, or buprenorphine.
- ^ US patent 4197239, Cavalla JF, Shepherd RG, White AC, "Hexahydroazepine, Piperidine and Pyrrolidine Derivatives", issued 1980-04-08, assigned to Wyeth
- ^ Holmes B, Ward A (1985). "Meptazinol. A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy". Drugs. 30 (4): 285–312. doi:10.2165/00003495-198530040-00001. PMID 2998723. S2CID 208818234.
- Meptazinol at the U.S. National Library of Medicine Medical Subject Headings (MeSH)